Study on Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly-Diagnosed Multiple Myeloma Patients

Inclusion Criteria

• Newly diagnosed with multiple myeloma, confirmed by lab tests, and have measurable disease.
• Show signs of organ damage or specific myeloma-related events, such as high calcium levels, anemia, bone damage, or a high percentage of plasma cells in the bone marrow.
• Kidney function must be adequate, with a creatinine clearance of at least 60 ml/min.
• Aged 18 to 75 years old.
• Good overall health with a performance status score of 0 to 2.
• Sufficient blood cell counts and liver function.
• Able to tolerate blood clot prevention medications like aspirin or other anticoagulants.
• Must be registered in a safety monitoring program and agree to follow its requirements.
• Women of childbearing potential must have a negative pregnancy test and agree to use effective birth control methods. Men must agree to use condoms during sexual activity.

Exclusion Criteria

• Have received more than one cycle of prior treatment for multiple myeloma.
• Have been treated with certain drugs like Daratumumab or other anti-CD38 therapies, unless part of a re-treatment study.
• Have plasma cell leukemia, POEMS syndrome, or amyloidosis.
• Have severe lung conditions like COPD with low lung function or uncontrolled asthma.
• Pregnant or breastfeeding women.
• Have uncontrolled high blood pressure or diabetes.
• Have active hepatitis B or C, or HIV infection.
• Have significant heart disease or recent heart attack.
• Have severe nerve damage or neuropathy.
• Have had major surgery within the last three weeks.